Ocular Surface Morbidities in Glaucoma
Abstract
Overview
Introduction: Ocular surface disease (OSD) is a major cause of ophthalmological consultation. Within this group, glaucoma patients constitute an important percentage due to the nature of their chronic topical treatment. Advances in the understanding of ocular surface pathology on both a cellular and molecular level, and the interaction to the toxic nature of some topical medication solution compounds, are stimulating the development of better alternatives in topical treatment.
Materials and Methods: Extensive review of available literature and current research on topical ophthalmological treatments in both OSD and glaucoma was performed. Emphasis was made on inflammatory modulators of the ocular surface and pathological changes associated with the use of preservatives in solutions, in particular benzalkonium chloride (BAK). Independent research is been also performed by the authors, using a rubbing-induced reflex tears collecting method with capillary tubes. Cytokines in tear samples were subsequently analysed with the multi-Plex System (Luminex®R-200). The 12 cytokines analysed using this method are the interleukins (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, the tumour necrosis factor alpha (TNFα), the vascular endothelial growth factor (VEGF), the granulocyte-macrophage-colony stimulating factor (GM-CSF) and the interferon gamma (IFg).
Results: Our unpublished, preliminary results trend to show higher values in IL-5 and IL-6 in glaucoma patients than in normal controls.
Also, higher values in IL-2, IL-5 and IL-12 in DES patients were found versus normal controls.
Conclusions: Inflammation is an important element in OSD and strong association seems to exist between this and the use of BAK
preservative. New kinds of preservative molecules, as well as single-dose eye drops and sophisticated dispensing bottle mechanisms are
currently available on the market in order to avoid the secondary effects of this topical treatments, increasing patient compliance and
adherence to chronic topical glaucoma treatment.
Keywords
Ocular surface, glaucoma, benzalkonium chloride, preservatives, conjunctiva, cornea, inflammation
Article Information
Disclosure
The authors have no conflicts of interest to declare.
Correspondence
Javier Benitez-del-Castillo, Plaza Monti, 7 Bajo, 11403 Jerez (Cadiz), Spain. E: javier.benitezdelcastillo@uca.es
Received
2012-11-05
Further Resources
Trending Topic
Dry eye disease (DED) is a prevalent ocular condition characterized by discomfort, visual disturbances and tear film instability due to insufficient tear production or rapid tear evaporation.1 With an increasing global incidence (i.e. up to 50%) and its significant impact on the quality of life, there is a growing need for accurate and efficient diagnostic methods to […]
Dry eye disease (DED) is a multifactorial condition of the ocular surface and tears. It is frequently encountered in ocular practices, comprising nearly 33% of visits in the USA, and with an estimated global prevalence ranging between 5% and 50%.1,2Â The chronic symptoms ...
Reproxalap is a reactive aldehyde species (RASP) inhibitor believed to mitigate inflammatory conditions such as dry eye disease (DED), allergic conjunctivitis and uveitis.1 RASP are pro-inflammatory molecules that covalently bind to thiol and amino groups expressed on various receptors and ...
Demodex blepharitis is a highly prevalent lid margin disease that is commonly missed or misdiagnosed by eye care professionals. The disease is caused by an infestation of Demodex mites – tiny parasites that live in the eyelash follicles and feed on ...
The prevalence of both dry eye disease and sleep apnoea has steadily increased in the USA.1Â Importantly, new research reveals the need for multispecialty collaboration based on evidence that patients may be at risk for eye irritation secondary to airflow ...
Dry eye disease (DED) is an inflammatory condition of the cornea and conjunctiva that is characterized by tear-film instability and increased tear osmolarity.1–3 While DED is traditionally viewed as a chronic condition, many patients experience episodic exacerbations of the disease, ...
Over the past few years, we have witnessed an increasing awareness of the importance of treating ocular surface disease (OSD). Diagnoses such as dry eye and blepharitis, which were historically under-appreciated, now command attention from the ophthalmologist and investment from ...
Dry eye disease is a chronic condition that affects the corneal surface, and is clinically characterized by loss of tear volume and increased evaporation of tears.1,2Â The definition of dry eye disease has evolved since it was first recognized over 30 ...
Dry eye is a common ocular condition that results in eye pain and discomfort, visual disturbance and substantially affects quality of life.1Â The incidence of dry eye is markedly increasing due to the expansion in the global internet network.2Â The ...
Introduction In the recently updated Dry Eye WorkShop DEWS II report, dry eye is defined as a multifactorial disease of the ocular surface characterized by loss of homeostasis of the tear film, accompanied by ocular symptoms, tear film instability, hyperosmolarity, ...
Dry eye disease (DED) is a common ocular condition with a high impact on visual function and quality of life.1 However, DED is one of the most misdiagnosed diseases because of a delay in symptoms and clinical signs, and the ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
